Moderna, Inc. (MRNA) stock
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30508% above fair value
$196.79−10.01 (-4.84%)
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
Moderna operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Moderna's operating cash flow for the twelve months ending Jun 30, 2026 was -$1.07B. For fiscal 2025 it was -$1.87B. The highest annual figure on record is $13.62B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.87B | – |
| FY2024 | Dec 31, 2024 | -$3.00B | – |
| FY2023 | Dec 31, 2023 | -$3.12B | -162.6% |
| FY2022 | Dec 31, 2022 | $4.98B | -63.4% |
| FY2021 | Dec 31, 2021 | $13.62B | +571.9% |
| FY2020 | Dec 31, 2020 | $2.03B | – |
| FY2019 | Dec 31, 2019 | -$459.00M | – |
| FY2018 | Dec 31, 2018 | -$330.87M | – |
| FY2017 | Dec 31, 2017 | -$331.48M | -596.7% |
| FY2016 | Dec 31, 2016 | $66.73M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$526.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$630.00M | – |
| Q4 FY2025 | Dec 31, 2025 | $930.00M | +12.7% |
| Q3 FY2025 | Sep 30, 2025 | -$847.00M | – |
| Q2 FY2025 | Jun 30, 2025 | -$919.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.04B | – |
| Q4 FY2024 | Dec 31, 2024 | $825.00M | +32.6% |
| Q3 FY2024 | Sep 30, 2024 | -$1.57B | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.27B | – |
| Q1 FY2024 | Mar 31, 2024 | -$989.00M | – |
| Q4 FY2023 | Dec 31, 2023 | $622.00M | -62.6% |
| Q3 FY2023 | Sep 30, 2023 | -$1.60B | -734.9% |
| Q2 FY2023 | Jun 30, 2023 | -$915.00M | -401.0% |
| Q1 FY2023 | Mar 31, 2023 | -$1.23B | -144.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.66B | -49.8% |
| Q3 FY2022 | Sep 30, 2022 | $252.00M | -92.3% |
| Q2 FY2022 | Jun 30, 2022 | $304.00M | -92.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.76B | -7.0% |
| Q4 FY2021 | Dec 31, 2021 | $3.31B | +161.9% |
| Q3 FY2021 | Sep 30, 2021 | $3.28B | +266.9% |
| Q2 FY2021 | Jun 30, 2021 | $4.06B | – |
| Q1 FY2021 | Mar 31, 2021 | $2.97B | – |
| Q4 FY2020 | Dec 31, 2020 | $1.26B | – |
| Q3 FY2020 | Sep 30, 2020 | $893.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.00M | – |
| Q1 FY2020 | Mar 31, 2020 | -$106.00M | – |
| Q4 FY2019 | Dec 31, 2019 | -$99.05M | – |
| Q3 FY2019 | Sep 30, 2019 | -$107.09M | – |
| Q2 FY2019 | Jun 30, 2019 | -$108.59M | – |
| Q1 FY2019 | Mar 31, 2019 | -$144.27M | – |
| Q4 FY2018 | Dec 31, 2018 | -$91.02M | – |
| Q3 FY2018 | Sep 30, 2018 | -$80.21M | – |
| Q2 FY2018 | Jun 30, 2018 | -$48.25M | – |
| Q1 FY2018 | Mar 31, 2018 | -$111.39M | – |
See a number that looks wrong?